Cel-Sci Corporation

Cel-Sci Corporation Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Cel-Sci Corporation, Medical Service, 8229 Boone Boulevard, Suite 802, Vienna, VA.

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI Reports Fiscal Second Quarter 2026 Results
05/18/2026

CEL-SCI Reports Fiscal Second Quarter 2026 Results

CEL-SCI reported financial results for three months ended March 31, 2026, as well as key corporate developments for Multikine.

CEL-SCI Corporation Announces Pricing of Public Offering
05/12/2026

CEL-SCI Corporation Announces Pricing of Public Offering

CEL-SCI Corporation Announces Pricing of Public Offering.

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in...
05/11/2026

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia.

CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmato...
02/18/2026

CEL-SCI is focused on two major value-driving milestones in the near term—starting enrollment in our U.S. FDA confirmatory Registration trial of Multikine in head and neck cancer and advancing Multikine globally in markets including Saudi Arabia.

CEL-SCI reported financial results for three months ended December 31, 2025, as well as key recent clinical and corporate developments.

CEL-SCI Reports Fiscal 2025 Results
12/29/2025

CEL-SCI Reports Fiscal 2025 Results

CEL-SCI Corporation reports financial results for the fiscal year ended September 30, 2025, as well as key clinical and corporate developments.

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025. You can register to watch the virt...
10/20/2025

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025. You can register to watch the virtual presentation at 9:30 a.m. PST by following this link: https://lnkd.in/g9ib3b4V.
https://www.newsfilecorp.com/release/270944

Vienna, Virginia--(Newsfile Corp. - October 20, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, previously...

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
10/10/2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Vienna, Virginia--(Newsfile Corp. - October 10, 2025) - CEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, today...

Geert Kersten, CEO of CEL-SCI, discusses the innovative approach of using immunotherapy, specifically Multikine, in canc...
09/24/2025

Geert Kersten, CEO of CEL-SCI, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer treatment. He emphasizes the importance of the immune system in fighting cancer and the need for a paradigm shift in how cancer therapies are developed and administered.

In this episode of Drug Diaries, Geert Kersten, CEO of Cel-Sci, discusses the innovative approach of using immunotherapy, specifically Multikine, in cancer t...

Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient...
08/13/2025

Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI’s Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia.

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head &...
07/11/2025

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI to sign partnership agreement with leading Saudi Arabian pharma company for Multikine in the treatment of head & neck cancer.

Address

8229 Boone Boulevard, Suite 802
Vienna, VA
22182

Opening Hours

Monday 9am - 5:30pm
Tuesday 9am - 5:30pm
Wednesday 9am - 5:30pm
Thursday 9am - 5:30pm
Friday 9am - 5:30pm

Telephone

+17035069460

Website

Alerts

Be the first to know and let us send you an email when Cel-Sci Corporation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category